Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | Unknown | — |
The patient received two doses of RabAvert in May-2024, for pre-exposure prophylaxis, and did not receive the third dose; Case reference number US-BN-2024-002193 is a spontaneous case initially received from pharmacist via Med Communications (reference number USBAV24-1664) on 15-Jul-2024 and concerns a 28-years-old female patient. The patient's medical history and concomitant medication details were not provided. On 23-May-2024, the patient was vaccinated with the first dose of RabAvert (batch number: unknown), at an unknown dose, route, or site of administration, for pre-exposure prophylaxis against rabies. On 30-May-2024, seven days after the first dose of RabAvert, the patient was vaccinated with the second dose of RabAvert (batch number: unknown), at an unknown dose, route, or site of administration. As reported, the vaccination with the first and the second dose of RabAvert was almost eight weeks ago and the patient never got the third dose (explicitly codes as 'incomplete course of vaccination'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to RabAvert vaccine. No further information was provided.; Reporter's Comments: A 28-years-old female patient never got the third dose of RabAvert which is considered as incomplete course of vaccination. Incomplete course of vaccination is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to RabAvert vaccine. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A 28-years-old female patient never got the third dose of RabAvert which is considered as incomplete course of vaccination. Incomplete course of vaccination is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to RabAvert vaccine. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None.